搜尋結果
Walker T. Liquid Lifting mit Polymilchsäure Akt Dermatol 2010; 36: 300. ... –304. Verdünnung ist die Substanz noch leichter injizierbar, die Nadeln verstopfen nicht so leicht. Die Applikation der gelösten Polymilchsäure darf nicht zu ober-flächlich erfolgen.
Journal: World Journal of Otorhinolaryngology - Head and Neck Surgery Article Title: Facial fillers: Relevant anatomy, injection techniques, and complications doi: 10.1002/wjo2.126 Figure Lengend Snippet: Summary of facial fillers. Article Snippet: Poly‐ l ‐lactic acid (PLLA) , Sculptra (Sanofi‐aventis) , Long lasting , Stimulates collagen production, higher viscosity, moderate to severe ...
2017年6月9日 · Sculptra Aesthetic则是Sculptra的美容适应症产品，其主要成分为PLLA聚乳酸。 于2010年7月获得FDA批准 用于注射填充浅至深层鼻唇沟及其他面部皱纹。 2011年8月，Valeant 以4.25亿美元收购了 Sanofi 在美国与加拿大的Dermik皮肤医学部门，以及Sculptra Aesthetic的全球所有权。
Our passion is to improve access to medicines and healthcare. Sanofi Patient Connection is an access and support program in the U.S., providing medication at no cost to eligible patients, helping patients understand their insurance coverage, and identifying additional resources patients may find helpful. Discover More.
2023年4月26日 · DALLAS, April 26, 2023 /PRNewswire/ -- Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Sculptra ® (injectable poly-L-lactic acid (PLLA-SCA)) for the ...
2023年4月26日 · Sculptra ® helps improve skin quality and results can last up to 2 years 1-2 The first and original PLLA collagen stimulator is now approved for the correction of fine lines and wrinkles in the full cheek area 3-4 Dallas, Texas – April 26, 2023 – Galderma announced today that the U.S. Food and Drug Administration (FDA) has approved Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) for ...
2010年2月23日 · Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leading global pharmaceutical company, that discovers, develops and distributes therapeutic solutions to improve the lives of everyone.
